Tech Company Financing Transactions

Volastra Therapeutics Funding Round

Volastra Therapeutics, based in New York, received $60 million from Arch Venture Partners, Eli Lilly and Company and Polaris Partners.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

1361 Amsterdam Ave. 520
New York, NY 10027
USA

Phone

(646) 344-1248

Website

www.volastratx.com

Email Address

[email protected]

Overview

Volastra Therapeutics is pioneering novel approaches to halt or prevent cancer metastasis, one of the major unsolved challenges in cancer treatment. Co-founders Lewis Cantley, Ph.D., Olivier Elemento, Ph.D. and Samuel Bakhoum, M.D., Ph.D., made seminal discoveries about the role of chromosomal instability in driving cancer spread.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Charles Hugh-Jones

        

Chief Scientific Officer

Michael Su

        

Vice President

Rumin Zhang

        

VP - Operations

Diane Tager

        

Browse more venture capital transactions:

Prev: 3/7/2023: Assured Allies venture capital transaction
Next: 3/7/2023: Growfin venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary